A Study of IBI3046 in Participants With Overweight or Obesity

NCT07809945 · Not yet recruiting

Last updated 2026-09-22

This clinical trial is testing the safety of the experimental drug IBI3046 in adults who are overweight or have obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 128 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-09 · est. completion 2028-10

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07809945 ↗

Description as written by the study sponsor.

This study evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of IBI3046 in Chinese overweight or obese participants, comprising four phases: single ascending dose (SAD), multiple ascending dose (MAD), IBI3046 administration after mazdutide discontinuation, and IBI3046 in combination with mazdutide

Treatments tested

IBI3046 Drug

subcutaneous injection
placebo Drug

subcutaneous injection

Main thing measured	Number of participants with Adverse Event
Sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Conditions studied	Obesity and Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07809945 ↗